Project Grant K23HL189267
- The National Heart, Lung, and Blood Institute awarded $777,498 to the University of North Carolina at Chapel Hill on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on multiscale integration of mucin secretion and ion transport rates in asthmatic mucus plug formation and persistence. The research tests the applicability of a biophysical paradigm called the "two-gel" paradigm to asthma pathogenesis, examining whether asthma mucus...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $1.121 million on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research examining how maternal depression intervention affects child respiratory health outcomes in a low-resource setting. The award funds an additional data collection wave of the ongoing BACHPAN birth cohort study in rural Pakistan, which comprises approximately 825...
- The National Institutes of Health National Heart, Lung and Blood Institute awarded The Johns Hopkins University $1,283,164 on September 23, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to establish a longitudinal cohort of prematurely born children in Bangladesh and assess the efficacy of antenatal corticosteroids (ACS) on lung development and respiratory infection incidence. The project, titled BILDING-ACTION (Bangladesh Infant Lung Development-ACS for Improving...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $750,330 on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate MUC5AC structure, function, interactome, and its role in airway obstruction. The research addresses the molecular mechanisms by which MUC5AC, an airway mucin, contributes to chronic obstructive pulmonary disease and asthma pathogenesis. The project will define MUC5AC's unique macromolecular...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $791,870 on September 1, 2026, to design and evaluate an enhanced electronic patient-reported outcome (EPRO) implementation for thoracic surgery patients titled "BETTER REMOTE MONITORING AFTER THORACIC SURGERY EVENTS" (BREATHE), funded under the Cardiovascular Diseases Research program (CFDA 93.837). The project addresses postoperative symptom burden in thoracic surgery patients...
- The National Heart Lung and Blood Institute awarded the University of North Carolina at Chapel Hill $777,419 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the muco-obstructive mechanisms underlying bronchiectasis and identify novel therapeutic targets. The research examines bronchiectasis pathogenesis through a revised conceptual model that integrates airway epithelial hypoxia, mucus hyperconcentration, osmotic pressure-driven airway...
- The National Heart, Lung, and Blood Institute awarded The University of Iowa $188,676 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a machine learning model and unified protocol to predict neonatal extubation readiness in premature infants. The award funds development and validation of a clinical decision support tool that integrates continuous vital sign data, ventilator data, and clinical information into a machine learning prediction model to...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Ann & Robert H Lurie Children's Hospital of Chicago $876,614 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a multisite prospective cohort study advancing acute respiratory infection treatment in pediatric invasive home mechanical ventilation. The research will enroll 400 children in English and Spanish language families using long-term home mechanical...
- The National Heart, Lung, and Blood Institute awarded $316,609 to Remplenish, Inc. on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a novel myofunctional nipple device for preventing obstructive sleep apnea in infants. The recipient will design and validate a low-risk, low-burden device that delivers myofunctional therapy—oropharyngeal exercises integrated into infant bottle feeding—as a non-invasive first-line treatment and preventive measure...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $618,352 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the mechanical regulation of endothelial lipid droplet metabolism and its role in vascular dysfunction. The research examines how oscillatory shear stress suppresses triglyceride hydrolysis by inactivating the transcription factor FOXO1, leading to lipid droplet accumulation in...
The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $200,137 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop non-invasive tools for assessing aspiration risk in infants with swallowing dysfunction. The project will refine and validate clinical scoring tools based on observable feeding variables and develop artificial intelligence-enabled cervical auscultation methods to detect aspiration during feeding. The work involves a prospective study at UNC Children's Hospital enrolling 150 infants undergoing videofluoroscopic swallow studies for suspected dysphagia. Researchers will conduct standardized clinical feeding evaluations and record cervical auscultation data using a wearable, multimodal digital stethoscope during swallow studies. The study will standardize human interpretation protocols for cervical auscultation recordings and train machine learning models to predict aspiration using multimodal auscultation data, validated against videofluoroscopic findings as the reference standard. The award addresses the clinical gap created by limited access to instrumental swallow studies—videofluoroscopic swallow studies and fiberoptic endoscopic evaluation of swallowing—which require trained specialists, incur high costs, and present safety concerns. The project aims to provide scalable, non-invasive methods to improve pulmonary outcomes in at-risk infant populations, including those born prematurely or experiencing respiratory distress. Performance occurs in Chapel Hill, North Carolina. The period of performance runs through June 30, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $200.1k | 8/26/26 |